Effective Impurity Management within Antibody Drug Conjugates (ADCs)
Skip to menu Skip to main content

Explore more:

Donate Join us

Effective Impurity Management within Antibody Drug Conjugates (ADCs)

Date

18–19 November 2026

Subject areas

Industry , Analytical , Sustainability

Location

Online

Effective Impurity Management within Antibody Drug Conjugates (ADCs) Main Image
Book now Event Information Search all events
Course tutors: Andrew Teasdale PhD<\/strong> has over 30 years\u2019 experience in the pharmaceutical industry as an analytical chemist and within quality assurance and regulatory roles. In his current role he chairs AstraZeneca\u2019s Impurity Advisory Group. Dr Teasdale has published a number of papers relating to mutagenic impurities, N Nitrosamines, extractables and leachables,\u00a0 and other impurity related matters.\u00a0 He is currently the chair of the\u00a0 Extractables and Leachables safety Information exchange (ELSIE) and also led a number of industry expert groups; these include both safety and quality groups within Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA), Product Quality Research Institute (PQRI) .\u00a0 Andrew has also represented EFPIA in ICH Q3C, Q3D and Q3E Expert working groups. He has also advanced a number of key scientific advancements in the control of impurities as the inventor of the purge factor concept and the instigator of the development of Elemental Impurities database for excipients.<\/p>\n

With over 50 scientific papers, he has also written 3 books:<\/p>\n

Genotoxic Impurities \u2013 Strategies for Identification and control. Editor A Teasdale. Publisher Wiley. ISBN 978-0-470-49919-1<\/p>\n

ICH Quality Guidelines \u2013 An Implementation Guide. Editors A Teasdale, D Elder, R W Nims. Publisher Wiley.\u00a0 ISBN 978-1-118-97111-6.<\/p>\n

Mutagenic Impurities \u2013 Strategies for Identification and Control Second Edition.\u00a0 Editor A Teasdale. Publisher Wiley. ISBN 978-1-119-55121-8<\/p>\n

Contact Andrew Teasdale<\/a><\/p>\n

 <\/p>\n"}" data-popup-custom="Single.tutorsPopupOpen">Dr Andrew Teasdale

The use of Antibody drug conjugates as therapeutic agents is hugely attractive, offering the potential to effective target delivery of a drug to specific site and thus improving efficacy while also reducing toxicity through off target effects. ADCs comprise of 3 components, a drug, a linker and a monoclonal antibody.  There are often viewed as a biologic and a small molecule and thus subject to a guidance / regulatory framework covering both.  But is this correct?

This Online course will examine the challenges posed in effective and appropriate management of impurities.  It will examine each type of Impurity, process and product related, and crucially, the risk posed by conjugated and non-conjugated impurities.  In an area lacking an appropriate guidance framework it will examine the latest thinking and how this could shape the future approach taken to effective impurity management 

This course will be held across four live sessions.  Dates and timings are as follows:

PST: 5.30am-9.30am | CST: 7.30am-11.30am | EST: 8.30am-12.30pm | GMT: 1.30pm-5.30pm | CET: 2.30pm-6.30pm

– Wednesday, November 18 – Thursday, November 19

Event details
Book now Event Information Search all events